Answers are grounded in this paper and cite their sources.
Antimicrobial peptides are emerging as critical alternatives to conventional antibiotics, particularly in the fight against multidrug-resistant pathogens, including Mycobacterium tuberculosis and Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp . While antimicrobial peptides are traditionally known for their membrane-disruptive properties, increasing evidence reveals a broader spectrum of intracellular and molecular actions that remain underexplored. This review aims to systematically examine the alternative mechanisms of antimicrobial peptides that extend beyond membrane disruption. The review then explores non-classical antimicrobial peptide activities, including cellular penetration and subcellular localization, interference with essential metabolic pathways (e.g., mycolic acid and protein synthesis), modulation of host cell signaling (autophagy, inflammation), and inhibition of bacterial virulence and persistence mechanisms. Case studies of specific antimicrobial peptides that act through these alternative pathways are presented, along with comparisons to traditional agents. Finally, we discuss the clinical potential of antimicrobial peptides, the pharmacokinetic and immunological challenges in their development, and current strategies to enhance intracellular efficacy and selectivity. Understanding the non-canonical mechanisms of antimicrobial peptides opens new avenues for antimicrobial therapy, particularly against intracellular and drug-resistant pathogens. This review underscores the need for deeper mechanistic studies and innovative drug design approaches to fully exploit the therapeutic potential of antimicrobial peptides beyond membrane disruption.
No takes yet. Share an insight, caveat, or question.
Jacinto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: